SG11201605810WA - Benzimidazol-2-amines as midh1 inhibitors - Google Patents
Benzimidazol-2-amines as midh1 inhibitorsInfo
- Publication number
- SG11201605810WA SG11201605810WA SG11201605810WA SG11201605810WA SG11201605810WA SG 11201605810W A SG11201605810W A SG 11201605810WA SG 11201605810W A SG11201605810W A SG 11201605810WA SG 11201605810W A SG11201605810W A SG 11201605810WA SG 11201605810W A SG11201605810W A SG 11201605810WA
- Authority
- SG
- Singapore
- Prior art keywords
- benzimidazol
- amines
- midh1
- inhibitors
- midh1 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14154680 | 2014-02-11 | ||
| EP14182002 | 2014-08-22 | ||
| PCT/EP2015/052676 WO2015121210A1 (en) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-amines as midh1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201605810WA true SG11201605810WA (en) | 2016-08-30 |
Family
ID=52462928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605810WA SG11201605810WA (en) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-amines as midh1 inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9957235B2 (en) |
| EP (1) | EP3105209B1 (en) |
| JP (1) | JP6534675B2 (en) |
| KR (1) | KR20160115991A (en) |
| CN (1) | CN106573897B (en) |
| AP (1) | AP2016009371A0 (en) |
| AU (1) | AU2015217788B2 (en) |
| BR (1) | BR112016018604A2 (en) |
| CA (1) | CA2939026A1 (en) |
| CL (1) | CL2016002033A1 (en) |
| CR (1) | CR20160361A (en) |
| CU (1) | CU24410B1 (en) |
| DO (1) | DOP2016000208A (en) |
| EA (1) | EA031655B1 (en) |
| IL (1) | IL246785A0 (en) |
| MX (1) | MX2016010474A (en) |
| PE (1) | PE20170143A1 (en) |
| PH (1) | PH12016501581A1 (en) |
| SG (1) | SG11201605810WA (en) |
| SV (1) | SV2016005257A (en) |
| TW (1) | TWI666202B (en) |
| UY (1) | UY35991A (en) |
| WO (1) | WO2015121210A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2939021C (en) | 2014-02-11 | 2022-07-12 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| CR20160361A (en) | 2014-02-11 | 2016-10-03 | Bayer Pharma AG | BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS |
| BR112017005238B1 (en) | 2014-09-19 | 2023-01-17 | Forma Therapeutics, Inc | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES, THEIR USE AND PHARMACEUTICAL COMPOSITION |
| US9815817B2 (en) | 2014-09-19 | 2017-11-14 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| JP6672288B2 (en) | 2014-10-23 | 2020-03-25 | バイエル・ファルマ・アクティエンゲゼルシャフト | 1-Cyclohexyl-2-phenylaminobenzimidazole as midh1 inhibitor for treatment of tumors |
| US10138226B2 (en) * | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| CA2988356A1 (en) * | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| JP6824952B2 (en) * | 2015-07-07 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | 2-aryl- and 2-arylalkyl-benzimidazole as mIDH1 inhibitors |
| EP3322694B1 (en) | 2015-07-16 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| EP3121166A1 (en) * | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201718513A (en) * | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | Method for preparing substituted 3-(2-anilino-1-cyclohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives |
| TW201708193A (en) * | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | Inhibiton of the mutated isocitrate dehydrogenase IDH1 R132H |
| BR112018015413A2 (en) * | 2016-02-09 | 2018-12-18 | Inventisbio Inc | indoleamine-2,3-dioxigenase (acid) inhibitors |
| WO2019015672A1 (en) * | 2017-07-21 | 2019-01-24 | 南京明德新药研发股份有限公司 | Pyridoimidazole compound and use thereof |
| EP3661559A1 (en) | 2017-08-01 | 2020-06-10 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Combination of midh1 inhibitors and dna hypomethylating agents (hma) |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| HUE061331T2 (en) | 2018-05-16 | 2023-06-28 | Forma Therapeutics Inc | Inhibiting mutant idh-1 |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| AU2019296173B2 (en) * | 2018-06-26 | 2022-01-06 | Kpc Pharmaceuticals, Inc. | Benzimidazole derivatives and use thereof as IDH1 inhibitors |
| TWI760017B (en) * | 2019-12-23 | 2022-04-01 | 大陸商昆藥集團股份有限公司 | Salt form, crystalline form of idh1 mutant inhibitor and preparation method thereof |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| EP4186525A4 (en) | 2020-07-21 | 2024-04-03 | Daiichi Sankyo Company, Limited | Combination drug of temozolomide and inhibitor of mutated idh1 enzyme |
| CN112062687B (en) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | Synthesis method of azasetron hydrochloride intermediate 3-amino-5-chloro-2-hydroxybenzoic acid methyl ester |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2643903A1 (en) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS |
| CN1161340C (en) | 1998-11-30 | 2004-08-11 | 先灵公司 | Benzimidazole compounds that are vitronectin receptor antagonists |
| US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
| WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP1487824B1 (en) | 2002-03-01 | 2007-06-20 | SmithKline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| EP1677791A4 (en) | 2003-10-31 | 2007-08-15 | Takeda Pharmaceutical | Nitrogen-containing fused heterocyclic compounds |
| WO2005121132A1 (en) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | Fused heterocyclic compound having anti-hcv effect |
| EP1810677A1 (en) | 2004-10-08 | 2007-07-25 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
| EP2457901A1 (en) | 2005-03-14 | 2012-05-30 | High Point Pharmaceuticals, LLC | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
| WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| WO2009059214A1 (en) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Abeta-binding small molecules |
| WO2009116074A2 (en) | 2008-02-13 | 2009-09-24 | Cadila Healthcare Limited | Substituted benzimidazoles as cannabinoid modulator |
| UY32138A (en) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | SUBSTITUTED AMIDES 2- (2,6-DICLORO-PHENYLAMINE) -6-FLUORO-1-METHYL-1H-BENCIMIDAZOL-5-CARBOXYL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
| UY32470A (en) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | DERIVATIVES OF 2- {2-CHLORINE-5 - [(REPLACED) METHYL] PHENYLAMINE} -1-METHYL] PHENYLAMINE} -1-METHYLBENCIMIDAZOL-5-CARBOXAMIDES-N- (SUBSTITUTED) AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS, COMPOSITIONS AND APPLIANCE |
| CN104219954B (en) * | 2009-06-23 | 2017-03-22 | 翻译基因组学研究院 | Benzamide derivatives |
| EP2509600B1 (en) | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2012172043A1 (en) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| CN102827170A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Active treatment compositions and use method thereof |
| CN103435554A (en) | 2013-09-06 | 2013-12-11 | 中国药科大学 | 2-phenylaminobenzimidazole compound and application thereof |
| CR20160361A (en) | 2014-02-11 | 2016-10-03 | Bayer Pharma AG | BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS |
| CA2939021C (en) | 2014-02-11 | 2022-07-12 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| JP6672288B2 (en) | 2014-10-23 | 2020-03-25 | バイエル・ファルマ・アクティエンゲゼルシャフト | 1-Cyclohexyl-2-phenylaminobenzimidazole as midh1 inhibitor for treatment of tumors |
| US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| CN107835637A (en) | 2015-05-18 | 2018-03-23 | 转化药物开发有限责任公司 | Heterocyclic compound as kinase inhibitor |
| JP7028765B2 (en) | 2015-05-22 | 2022-03-02 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | Benzamide and active compound compositions and methods of use |
| CA2988356A1 (en) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| JP6824952B2 (en) | 2015-07-07 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | 2-aryl- and 2-arylalkyl-benzimidazole as mIDH1 inhibitors |
| EP3322694B1 (en) | 2015-07-16 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| TW201718513A (en) | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | Method for preparing substituted 3-(2-anilino-1-cyclohexyl-1H-benzimidazol-5-yl)propanoic acid derivatives |
| TW201708193A (en) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | Inhibiton of the mutated isocitrate dehydrogenase IDH1 R132H |
| EP3423439A4 (en) | 2016-03-02 | 2019-08-14 | Translational Drug Development Llc | Aminobenzimidazole derivatives |
-
2015
- 2015-02-10 CR CR20160361A patent/CR20160361A/en unknown
- 2015-02-10 CA CA2939026A patent/CA2939026A1/en not_active Abandoned
- 2015-02-10 AP AP2016009371A patent/AP2016009371A0/en unknown
- 2015-02-10 BR BR112016018604A patent/BR112016018604A2/en not_active Application Discontinuation
- 2015-02-10 KR KR1020167024825A patent/KR20160115991A/en not_active Application Discontinuation
- 2015-02-10 JP JP2016551221A patent/JP6534675B2/en not_active Expired - Fee Related
- 2015-02-10 US US15/118,154 patent/US9957235B2/en active Active
- 2015-02-10 EP EP15703288.9A patent/EP3105209B1/en active Active
- 2015-02-10 PE PE2016001465A patent/PE20170143A1/en unknown
- 2015-02-10 MX MX2016010474A patent/MX2016010474A/en unknown
- 2015-02-10 CU CU2016000120A patent/CU24410B1/en unknown
- 2015-02-10 AU AU2015217788A patent/AU2015217788B2/en not_active Ceased
- 2015-02-10 EA EA201691590A patent/EA031655B1/en not_active IP Right Cessation
- 2015-02-10 CN CN201580019265.9A patent/CN106573897B/en not_active Expired - Fee Related
- 2015-02-10 WO PCT/EP2015/052676 patent/WO2015121210A1/en active Application Filing
- 2015-02-10 SG SG11201605810WA patent/SG11201605810WA/en unknown
- 2015-02-11 TW TW104104623A patent/TWI666202B/en not_active IP Right Cessation
- 2015-02-11 UY UY0001035991A patent/UY35991A/en not_active Application Discontinuation
-
2016
- 2016-07-14 IL IL246785A patent/IL246785A0/en unknown
- 2016-08-10 PH PH12016501581A patent/PH12016501581A1/en unknown
- 2016-08-11 SV SV2016005257A patent/SV2016005257A/en unknown
- 2016-08-11 CL CL2016002033A patent/CL2016002033A1/en unknown
- 2016-08-11 DO DO2016000208A patent/DOP2016000208A/en unknown
-
2018
- 2018-03-16 US US15/923,895 patent/US10442772B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CU24410B1 (en) | 2019-05-03 |
| CR20160361A (en) | 2016-10-03 |
| IL246785A0 (en) | 2016-08-31 |
| US10442772B2 (en) | 2019-10-15 |
| CA2939026A1 (en) | 2015-08-20 |
| CN106573897B (en) | 2019-09-24 |
| US20170197921A1 (en) | 2017-07-13 |
| AU2015217788B2 (en) | 2019-06-27 |
| CN106573897A (en) | 2017-04-19 |
| BR112016018604A2 (en) | 2017-08-08 |
| UY35991A (en) | 2015-09-30 |
| AU2015217788A1 (en) | 2016-08-04 |
| CU20160120A7 (en) | 2016-12-23 |
| PE20170143A1 (en) | 2017-03-19 |
| MX2016010474A (en) | 2016-10-31 |
| JP2017505790A (en) | 2017-02-23 |
| US20190062285A1 (en) | 2019-02-28 |
| US9957235B2 (en) | 2018-05-01 |
| SV2016005257A (en) | 2018-10-02 |
| TWI666202B (en) | 2019-07-21 |
| DOP2016000208A (en) | 2016-09-15 |
| AP2016009371A0 (en) | 2016-08-31 |
| JP6534675B2 (en) | 2019-06-26 |
| EA031655B1 (en) | 2019-02-28 |
| KR20160115991A (en) | 2016-10-06 |
| EP3105209B1 (en) | 2019-08-21 |
| CL2016002033A1 (en) | 2017-03-31 |
| WO2015121210A1 (en) | 2015-08-20 |
| EA201691590A1 (en) | 2017-02-28 |
| EP3105209A1 (en) | 2016-12-21 |
| PH12016501581A1 (en) | 2017-02-06 |
| TW201613874A (en) | 2016-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | Smyd inhibitors | |
| IL277167B (en) | Cyclopropylamines as lsd1 inhibitors | |
| IL277299B (en) | Cyclopropylamines as lsd1 inhibitors | |
| IL246785A0 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| IL251420A0 (en) | Triazolopyrazinones as pde1 inhibitors | |
| HK1226398A1 (en) | Benzimidazol-2-amines as midh1 inhibitors | |
| IL251932B (en) | Benzylpropargylether as nitrification inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol -kinase inhibitors | |
| EP3183255C0 (en) | Spiropyrrolidines as mdm2 inhibitors | |
| SG11201609350XA (en) | Methods for inhibiting necroptosis | |
| GB201403536D0 (en) | Inhibitor compounds | |
| GB201501004D0 (en) | Inhibitors | |
| HUE045220T2 (en) | Imidazopyridazine derivatives as pi3kbeta inhibitors | |
| HK1232214A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors pde1 | |
| GB201520949D0 (en) | Inhibitors | |
| GB201401005D0 (en) | Inhibitor | |
| GB201418154D0 (en) | Inhibitors | |
| GB201407585D0 (en) | SMA-Inter Act |